Trials / Terminated
TerminatedNCT05580692
A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)
A Multinational, Multi-center, Prospective Cohort Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV) Serotypes in Subjects With Hemophilia A
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 321 (actual)
- Sponsor
- BioMarin Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A prospective cohort study utilizing biospecimen sample collection from adult Hemophilia A subjects to evaluate and characterize seroprevalence and the seroconversion of antibodies against AAV serotypes
Detailed description
This is a multinational, multi-center, prospective cohort study utilizing biospecimen sample collection from adult Hemophilia A subjects to evaluate and characterize seroprevalence and the seroconversion of antibodies against AAV serotypes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Biospecimen Collection | Biospecimen Sample Collection |
Timeline
- Start date
- 2023-03-14
- Primary completion
- 2024-07-31
- Completion
- 2024-07-31
- First posted
- 2022-10-14
- Last updated
- 2024-08-19
Locations
18 sites across 7 countries: Argentina, Australia, Austria, Saudi Arabia, Sweden, Turkey (Türkiye), United Arab Emirates
Source: ClinicalTrials.gov record NCT05580692. Inclusion in this directory is not an endorsement.